Teneligliptin

Teneligliptin (INN; trade name Tenelia) is a pharmaceutical drug for the treatment of type 2 diabetes mellitus. It belongs to the class of anti-diabetic drugs known as dipeptidyl peptidase-4 inhibitors or "gliptins".[1]

Teneligliptin
Clinical data
Trade namesTenelia
Legal status
Legal status
  • Approved in Japan
Identifiers
CAS Number
PubChem CID
ChemSpider
Chemical and physical data
FormulaC22H30N6OS
Molar mass426.58 g/mol g·mol−1
3D model (JSmol)

Creation

It was created by Mitsubishi Tanabe Pharma and launched in September 2012 by both Mitsubishi Tanabe Pharma and Daiichi Sankyo in Japan.[2]

Licensing and use

Japan/Korea/India/Argentina

It is approved for use in Japan, Argentina, Korea and India.[3]

Pharmacology

Teneligliptin has unique J shaped or anchor locked domain structure because of which it has a potent inhibition of DPP 4 enzyme.

Teneligliptin significantly controls glycemic parameters with safety. No dose adjustment is required in renally impaired patients.[4]

References

  1. Kishimoto, M (2013). "Teneligliptin: A DPP-4 inhibitor for the treatment of type 2 diabetes". Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 6: 187–95. doi:10.2147/DMSO.S35682. PMC 3650886. PMID 23671395.
  2. "TENELIA® 20mg tablets, a Treatment for Type 2 Diabetes Mellitus Approval of Partial Change in Indication to Lift Restrictions in Combination Therapy - Media & Investors - Daiichi Sankyo".
  3. Joanne Bronson; Amelia Black; T. G. Murali Dhar; Bruce A. Ellsworth; J. Robert Merritt (2013). Teneligliptin (Antidiabetic), Chapter: To Market, To Market - 2012. Annual Reports in Medicinal Chemistry. 48. pp. 523–524. doi:10.1016/b978-0-12-417150-3.00028-4. ISBN 9780124171503.
  4. Nabeno, Mika; Akahoshi, Fumihiko; Kishida, Hiroyuki; Miyaguchi, Ikuko; Tanaka, Yoshihito; Ishii, Shinichi; Kadowaki, Takashi (2013). "A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site". Biochemical and Biophysical Research Communications. 434 (2): 191–196. doi:10.1016/j.bbrc.2013.03.010.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.